Home/ Stocks/ VRDN

Viridian Therapeutics, Inc. Common Stock

VRDN XNAS

$23.59 +1.16 (+5.15%) ▲ 15-min delayed

Open

$22.98

High

$23.61

Low

$22.53

Volume

1.66M

Market Cap

$2.55B

About Viridian Therapeutics, Inc. Common Stock

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 252 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$141.0K	$-104,901,000	N/A
FY 2025	$70.85M	$-342,601,000	N/A
Q3 2025	$70.57M	$-34,599,000	N/A
Q2 2025	$75.0K	$-100,735,000	N/A

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for VRDN yet. Check out our latest market news or earnings calendar.

Get VRDN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Viridian Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.